Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study To Investigate The Safety And Efficacy Of CP-690,550 In Subjects With Moderate To Severe Crohn's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 24 Mar 2012 This trial is recruiting in Spain and France.
- 10 May 2011 Results presented at Digestive Disease Week 2011.
- 17 Dec 2009 Primary endpoint 'Crohn's-Disease-Activity-Index' has not been met.